A Study of LY3502970 in Participants With Type 2 Diabetes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

68 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-10-08

Study Completion Date

2021-07-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to learn more about the safety of LY3502970 and any side effects that might be associated with it. Blood tests will be done to measure how much LY3502970 is in the bloodstream, how long it takes the body to eliminate it, and how it affects blood sugar. Participation could last up to 18 weeks and may include up to 14 visits (including three overnight stays) in the study center.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of LY3305677 in Participants With Type 2 Diabetes

NCT03928379

Diabetes Mellitus, Type 2

COMPLETED PHASE1

A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus

NCT04450394

Type 2 Diabetes Mellitus

COMPLETED PHASE2

A Study of LY3209590 in Participants With Type 2 Diabetes

NCT03367377

Diabetes Mellitus, Type 2

COMPLETED PHASE1

A Study of Multiple Doses of LY2922470 in Participants With Diabetes

NCT01867216

Diabetes Mellitus, Type 2

COMPLETED PHASE1

A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 Diabetes

NCT02020616

Type 2 Diabetes Mellitus

TERMINATED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LY3502970

LY3502970 administered orally.

Group Type EXPERIMENTAL

LY3502970

Intervention Type DRUG

Administered orally.

Placebo

Placebo administered orally.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered orally.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY3502970

Administered orally.

Intervention Type DRUG

Placebo

Administered orally.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have type 2 diabetes mellitus (T2DM) for at least 6 months
* Have a glycated hemoglobin (HbA1c) value at screening of greater than or equal to (≥)7.0 percent (%) and less than or equal to (≤)10.5% and are treated with diet and exercise alone or a stable dose of metformin for at least 3 months prior to screening
* Have a body weight of ≥45 kilograms (kg) and have a body mass index of 18.5 to 45 kilograms per square meter (kg/m²), inclusive
* Have had a stable body weight for the 3 months prior to screening (less than \[\<\]5% body weight change)
* Males and females (not considered woman of childbearing potential)

Exclusion Criteria

* Have type 1 diabetes mellitus, latent autoimmune diabetes in adults or have had an episode of ketoacidosis or hyperosmolar state requiring hospitalization in the 6 months prior to screening
* Have had any of the following within the past 6 months prior to screening: myocardial infarction, unstable angina, coronary artery bypass graft, percutaneous coronary intervention (diagnostic angiograms are permitted), transient ischemic attack, cerebrovascular accident or decompensated congestive heart failure, or currently have New York Health Association Class III or IV heart failure
* Show evidence of hepatitis B, and/or positive hepatitis B surface antigen
* Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies
* Any glucose-lowering medications other than metformin within 3 months prior to screening

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No